Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming ESGO Meeting

Aeterna Zentaris Inc. AEZS today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological Oncology to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy. The trial was conducted by the German AGO Study Group and study centers in Bulgaria. AEZS-108, a targeted cytotoxic peptide conjugate, is currently in Phase 1/2 programs in prostate and bladder cancer, and has successfully completed Phase 2 trials in endometrial and ovarian cancer.